These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35122491)

  • 1. An assessment of liver lesions using a combination of CEUS LI-RADS and AFP.
    Li CQ; Huang H; Ruan SM; Hu HT; Xian MF; Xie XY; Lu MD; Kuang M; Wang Y; Chen LD
    Abdom Radiol (NY); 2022 Apr; 47(4):1311-1320. PubMed ID: 35122491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Value of CEUS LI-RADS combined with AFP in early diagnosis of hepatocellular carcinoma in low- and high-risk patients.
    Wu Y; Chen Y; Wei L; Ding Z; Zhao S; Bao S; Tang J; Li H; Liu J; Zhu S
    J Cancer Res Ther; 2024 Aug; 20(4):1274-1283. PubMed ID: 38958652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis.
    Vidili G; Arru M; Solinas G; Calvisi DF; Meloni P; Sauchella A; Turilli D; Fabio C; Cossu A; Madeddu G; Babudieri S; Zocco MA; Iannetti G; Di Lembo E; Delitala AP; Manetti R
    World J Gastroenterol; 2022 Jul; 28(27):3488-3502. PubMed ID: 36158272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
    Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
    World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.
    Huang JY; Li JW; Lu Q; Luo Y; Lin L; Shi YJ; Li T; Liu JB; Lyshchik A
    Radiology; 2020 Feb; 294(2):329-339. PubMed ID: 31793849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
    Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining serum AFP and CEUS LI-RADS for better diagnostic performance in Chinese high-risk patients.
    Gong W; Wu J; Wei H; Jiang Z; Wan M; Wu C; Xue W; Ma R; Zhou X; Zhou H
    Radiol Med; 2023 Apr; 128(4):393-401. PubMed ID: 36943653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LR-M Observations on Contrast-Enhanced Ultrasound: Detection of Hepatocellular Carcinoma Using Additional Features in Comparison With Current LI-RADS Criteria.
    Xian MF; Huang Y; Xie WX; Pan KM; Zeng D; Huang H; Li MD; Xie XY; Kuang M; Lu MD; Chen LD; Wang W
    AJR Am J Roentgenol; 2022 Jul; 219(1):76-85. PubMed ID: 34910538
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients.
    Darnell A; Rimola J; Belmonte E; Ripoll E; Garcia-Criado Á; Caparroz C; Díaz-González Á; Vilana R; Reig M; Ayuso C; Bruix J; Forner A
    Eur Radiol; 2021 Jul; 31(7):4794-4803. PubMed ID: 33409789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CEUS LI-RADS in Combination With the Serum Biomarker-Based ASAP Model Improves the Diagnostic Performance of HCC in High-Risk Patients.
    Wen R; Peng Y; Liang Y; Wu Y; Li H; Chen Y; Qin Y; Wen Z; Cui H; He Y; Yang H
    Ultrasound Med Biol; 2024 Nov; 50(11):1739-1744. PubMed ID: 39181805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast-enhanced US diagnostic algorithm of hepatocellular carcinoma in patients with occult hepatitis B.
    Huang Y; Li W; Hu HT; Ruan SM; Xian MF; Xie XY; Lu MD; Kuang M; Chen LD; Wang W
    Abdom Radiol (NY); 2022 Feb; 47(2):608-617. PubMed ID: 34800160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Yang J; Zhang YH; Li JW; Shi YY; Huang JY; Luo Y; Liu JB; Lu Q
    World J Gastroenterol; 2020 Dec; 26(46):7325-7337. PubMed ID: 33362387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of current versus modified CEUS LI-RADS in the diagnosis of non-hepatocellular carcinoma malignancies.
    Wen R; Huang F; Lin P; Gao R; Pang J; Wu Y; Yin H; Tang Z; Ma Z; He Y; Yang H
    Abdom Radiol (NY); 2023 Dec; 48(12):3688-3695. PubMed ID: 37726380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiation between combined hepatocellular carcinoma and hepatocellular carcinoma: comparison of diagnostic performance between ultrasomics-based model and CEUS LI-RADS v2017.
    Li CQ; Zheng X; Guo HL; Cheng MQ; Huang Y; Xie XY; Lu MD; Kuang M; Wang W; Chen LD
    BMC Med Imaging; 2022 Mar; 22(1):36. PubMed ID: 35241004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
    Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
    Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features.
    Jiang H; Song B; Qin Y; Chen J; Xiao D; Ha HI; Liu X; Oloruntoba-Sanders O; Erkanli A; Muir AJ; Bashir MR
    Eur Radiol; 2021 Jun; 31(6):3638-3648. PubMed ID: 33245494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma.
    Wen R; Lin P; Wu Y; Yin H; Huang W; Guo D; Peng Y; Liu D; He Y; Yang H
    Eur J Radiol; 2022 Sep; 154():110415. PubMed ID: 35738166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.
    Zou X; Luo Y; Morelli JN; Hu X; Shen Y; Hu D
    Abdom Radiol (NY); 2021 Jul; 46(7):3168-3178. PubMed ID: 33660040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
    Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
    Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of contrast-enhanced ultrasound LI-RADS version 2017: application on 271 liver nodules in individuals with non-alcoholic steatohepatitis.
    Huang Z; Zhou P; Li S; Li K
    Eur Radiol; 2022 Oct; 32(10):7146-7154. PubMed ID: 35639147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.